DHR Health Institute for Research and Development Recognized as a “Top Performing Site” Once Again

Translate to Spanish or other 102 languages!

THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development is delighted to announce that it has once again been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This marks the third consecutive time the Institute has received this prestigious distinction.

This recognition highlights the ongoing excellence and impact of the Research Institute as it continues to advance cancer research and improve patient outcomes.

“We are deeply honored and this recognition would not be possible without the assistance of the DHR Health Oncology Institute and the leadership of Dr. Jose Cruz,” said Dr. Scott Lillibridge, executive vice president for the DHR Health Institute for Research and Development.

- Advertisement -

SWOG is a global cancer research community supported by the National Cancer Institute (NCI), and recognition as a “Top Performing Site” signifies exceptional performance in clinical trial enrollment, data quality, and patient care standards.

The DHR Health Institute for Research and Development remains committed to innovation and delivering high-quality research opportunities to all residents of the Rio Grande Valley. They are located at 5323 S. McColl Road in Edinburg. For more information about clinical trials in the areas of liver, obesity, cancer, neurology, oncology and urology, call the Institute at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.
- Advertisement -